我們已在上線! 進一步了解
AERI

Aerie Pharmaceuticals

已下市

AERI已於2022年11月18日下市。

 

關於: Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

員工: 376

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於AERI的最新新聞文章。

價格圖表採用Lightweight Charts™實作